---
title: "Craig-Hallum 维持对 Neurogene（NGNE）的买入评级"
description: "根据 TipRanks 的数据，Sigdahl 是一位五星级分析师，平均回报率为 11.8%，成功率为 46.45%。Sigdahl 覆盖消费周期性行业，专注于 Flutter Entertainment PLC、Super Group (SGHC) 和 Inspired Entertainment 等股票。Neurogene 的分析师共识为强烈买入，目标价格共识为 53.67 美元，比当前水平有"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/260470358.md"
published_at: "2025-10-09T13:15:43.000Z"
---

# Craig-Hallum 维持对 Neurogene（NGNE）的买入评级

> 根据 TipRanks 的数据，Sigdahl 是一位五星级分析师，平均回报率为 11.8%，成功率为 46.45%。Sigdahl 覆盖消费周期性行业，专注于 Flutter Entertainment PLC、Super Group (SGHC) 和 Inspired Entertainment 等股票。Neurogene 的分析师共识为强烈买入，目标价格共识为 53.67 美元，比当前水平有 107.78% 的上涨空间。在今天发布的一份报告中，H.C. Wainwright 也重申了对该股票的买入评级，目标价格为 45.00 美元

根据 TipRanks 的数据，Sigdahl 是一位五星级分析师，平均回报率为 11.8%，成功率为 46.45%。Sigdahl 覆盖消费周期性行业，专注于 Flutter Entertainment PLC、Super Group (SGHC) 和 Inspired Entertainment 等股票。

Neurogene 的分析师共识为强烈买入，目标价格共识为 53.67 美元，比当前水平有 107.78% 的上涨空间。在今天发布的一份报告中，H.C. Wainwright 也重申了对该股票的买入评级，目标价格为 45.00 美元。

### Related Stocks

- [NGNE.US - Neurogene](https://longbridge.com/zh-CN/quote/NGNE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Neurogene Maps NGN-401 Pivotal Rett Timeline, Mid-2026 Data Update at Guggenheim Summit | Neurogene (NASDAQ: NGNE) is advancing its genetic medicines pipeline, focusing on Rett syndrome with its lead program NG | [Link](https://longbridge.com/zh-CN/news/275981671.md) |
| BofA Reaffirms Glencore at Buy Amid Rumored Kazzinc Stake Sale | BofA Reaffirms Glencore at Buy Amid Rumored Kazzinc Stake Sale | [Link](https://longbridge.com/zh-CN/news/275470915.md) |
| 2 red-hot growth stocks to buy in 2026 | These stocks have roared higher but still have room to run. | [Link](https://longbridge.com/zh-CN/news/275694569.md) |
| J.P. Morgan Sticks to Their Buy Rating for Rio Tinto (RIO) | J.P. Morgan analyst Dominic OKane has reaffirmed a Buy rating for Rio Tinto (RIO) with a price target of p8,010.00. OKan | [Link](https://longbridge.com/zh-CN/news/275680099.md) |
| Differentiated NMRA-511 Efficacy and Safety in Alzheimer’s Agitation Support Buy Rating on Neumora | Needham analyst Ami Fadia has maintained a Buy rating on Neumora Therapeutics, Inc. with a price target of $8.00, citing | [Link](https://longbridge.com/zh-CN/news/275644413.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。